Brand-name drug
Aranesp price, strengths & recalls
Brand of darbepoetin alfa (generic)
Pharmacies pay $1,203.90 for 1.6 mL of Aranesp 0.1 mg/mL, 0.4 mL prefilled syringe this week, and from $750.80 to $1,800.18 across its 3 priced strengths and forms. Its official label last changed on July 21, 2026.
Brand- Fair cash price
- $1,394.98
- Strengths
- 3
- Makers
- 1
- Updated
- Nov 11
Aranesp price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 0.025 mg/mL, 1 mL injection Brand | Not priced this week | |||
| 0.06 mg/mL, 0.42 mL prefilled syringe Brand | $446.90 | $750.80 / 1.68 mL | ||
| 0.1 mg/mL, 0.4 mL prefilled syringe Brand | $752.44 | $1,203.90 / 1.6 mL | ||
| 0.2 mg/mL, 0.3 mL prefilled syringe Brand | $1,500.15 | $1,800.18 / 1.2 mL | ||
Aranesp vs generic darbepoetin alfa
There is no generic version of Aranesp on the market yet.
GenericDarbepoetin alfa pricesSupply status: shortages & recalls
What people paid for Aranesp
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ARANESP safely and effectively. See full prescribing information for ARANESP. ARANESP® (darbepoetin alfa) injection, for intravenous or subcutaneous useInitial U.S. Approval: 2001
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Chronic Kidney Disease:
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions (5.1)].
No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration (2.2)].
Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions (5.2)].
To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.3)].
Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage (1.2)].
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage (1.3)].
Discontinue following the completion of a chemotherapy course [see Dosage and Administration (2.3)].
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Chronic Kidney Disease:
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1).
No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks (2.2).
Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions (5.1).
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2).
Use the lowest dose to avoid RBC transfusions (2.3).
Use ESAs only for anemia from myelosuppressive chemotherapy (1.2).
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.3).
Discontinue following the completion of a chemotherapy course (2.3).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- BLA103951 · Amgen
- First approved
- September 17, 2001 (25 years ago)
- Latest approved change
- April 30, 2024
- Approved label
- PDF, Jun 5, 2019
- Generic makers
- None on the market
Aranesp questions
How much does aranesp cost without insurance?
Pharmacies pay about $1,203.90 for 1.6 mL of aranesp 0.1 mg/mL, 0.4 mL prefilled syringe ($752.44 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,394.98. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Aranesp?
Yes: darbepoetin alfa. Compare darbepoetin alfa prices.
Is aranesp in shortage?
No shortage is reported for aranesp right now. We check the national shortage list every day.
Has aranesp been recalled?
No recalls are on record for aranesp.
When did the aranesp label last change?
The official label was last updated on July 21, 2026 (version 161). See what changed.
Talk about aranesp
No comments yet. Questions, tips, what worked for you - start the conversation.